BRD4-TARGETED THERAPY ABBV-744 CLINICAL DATA NO FURTHER A MYSTERY

The current work examined the potential of using ARV-825 and ABBV-744 to enhance the effectiveness of tamoxifen or fulvestrant furthermore palbociclib. ARV-825 was effective in both equally p53 wild-style (WT) breast tumor cells and in cells missing functional p53 either on your own or in combination with tamoxifen, even though the effectiveness of